Now, in a note out Tuesday morning, SVB Leerink analyst Geoffrey Porges argues that Alexion’s (ticker: ALXN) acquisitions aren’t working, and that the whole capital allocation strategy needs a revamp.“We believe significant value lies ahead as we continue to execute on our strategy of diversifying beyond [C5 complement inhibitors Soliris and Ultomiris] to create shareholder value,” Alexion told Barron’s.